Anthropometric, Metabolic and Molecular Determinants of Human Epidermal Growth Factor Receptor 2 Expression in Luminal B Breast Cancer-Reference-Cited by-同舟云学术

Anthropometric, Metabolic and Molecular Determinants of Human Epidermal Growth Factor Receptor 2 Expression in Luminal B Breast Cancer

Published:2015-04-27 Issue:8 Volume:230 Page:1708-1712
ISSN:0021-9541
Container-title:Journal of Cellular Physiology
language:en
Short-container-title:J. Cell. Physiol.

Author:

Vici Patrizia¹,Crispo Anna²,Giordano Antonio³⁴,Lauro Luigi Di¹,Sperati Francesca⁵,Terrenato Irene⁵,Pizzuti Laura¹,Sergi Domenico¹,Mottolese Marcella⁶,Botti Claudio⁷,Grimaldi Maria²,Capasso Immacolata⁸,D'Aiuto Giuseppe⁸,Bonito Maurizio Di⁹,Paola Flaviano Di¹⁰,Maugeri-Saccà Marcello¹¹,Montella Maurizio²,Barba Maddalena¹¹

Affiliation:

1. Division of Medical Oncology B; Regina Elena National Cancer Institute; Rome Italy

2. Epidemiology Unit; G. Pascale Foundation National Cancer Institute; Naples Italy

3. Sbarro Institute for Cancer Research and Molecular Medicine and Center of Biotechnology; College of Science and Technology Temple University; Philadelphia Pennsylvania

4. Department of Human Pathology and Oncology; University of Siena; Siena Italy

5. Biostatistics-Scientific Direction; Regina Elena National Cancer Institute; Rome Italy

6. Department of Pathology; Regina Elena National Cancer Institute; Rome Italy

7. Department of Surgery; Regina Elena National Cancer Institute; Rome Italy

8. Breast Unit; G. Pascale Foundation National Cancer Institute; Naples Italy

9. Department of Pathology; G. Pascale Foundation National Cancer Institute; Naples Italy

10. Department of Diagnostics and Clinical Pathology; G. Pascale Foundation National Cancer Institute; Naples Italy

11. Division of Medical Oncology B-Scientific Direction; Regina Elena National Cancer Institute; Rome Italy

Publisher

Wiley

Subject

Cell Biology,Clinical Biochemistry,Physiology

Reference43 articles.

1. Insulin resistance and breast carcinogenesis: A cross-sectional study among Iranian women with breast mass;Abbasi;Metab Syndr Relat Disord,2010

2. Luminal B breast cancer: Molecular characterization, clinical Management, and future perspectives;Ades;J Clin Oncol,2014

3. Clinical practice recommendations;American Diabetes;Diabetes Care,2008

4. Sequence analysis of mutations and translocations across breast cancer subtypes;Banerji;Nature,2012

5. Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: Results from a historic cohort;Barba;Ann Oncol,2012

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab;Cancer Biology & Therapy;2018-02-16

2. Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study;Scientific Reports;2017-09-06

3. Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer;BMC Cancer;2017-02-06

4. Neoadjuvant Sequential Docetaxel Followed by High‐Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial;Journal of Cellular Physiology;2016-06-02

5. Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin;Journal of Cellular Physiology;2015-11-20